The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s duchenne muscular dystrophy market report forecasts the duchenne muscular dystrophy market size to grow to $1.48 Billion by 2027, with a CAGR (compound annual growth rate) of more than 8%.

Learn More On The Duchenne Muscular Dystrophy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

Duchenne Muscular Dystrophy Market Size Forecast
The global duchenne muscular dystrophy market is expected to grow from $0.98 billion in 2022 to $1.07 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global duchenne muscular dystrophy market size is expected to reach $1.48 billion in 2027 at a CAGR of 8.3%.

North America held the largest duchenne muscular dystrophy market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Duchenne Muscular Dystrophy Market Driver ­– Rise In The Prevalence Of Duchenne Muscular Dystrophy
For example, according to the Orphanet Journal of Rare Diseases report published in June 2020 by BioMed Central, a UK-based company that publishes open-access scientific journals, the global prevalence of Duchenne muscular dystrophy in June 2020 was 7.1 cases per 100,000 males and 2.8 cases per 100,000 in the general population. Furthermore, the global birth prevalence of Duchenne muscular dystrophy was 19.8 per 100,000 live male births. As a result, the growing prevalence of Duchenne muscular dystrophy is propelling the market for Duchenne muscular dystrophy.

Request for A Sample Of The Global Duchenne Muscular Dystrophy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10368&type=smp

Key Duchenne Muscular Dystrophy Market Trend – Technological Advancement
To maintain their market position, major businesses in the Duchenne muscular dystrophy market are focusing more on technological improvements and research and development. For example, the University of Texas Southwestern’s Hamon Centre for Regenerative Science and Medicine, a US-based public academic health science centre, announced in April 2021 the launch of a new type of gene therapy to treat mice with Duchenne muscular dystrophy (DMD) by using CRISPR-Cas9-based techniques to restore a significant portion of the dystrophin protein that is missing in many DMD patients. The researchers developed a number of successful CRISPR-Cas9 nucleotide gene editing approaches to overcome the erroneous “stop” signal, restoring 97% of the protein’s production. They swiftly studied nucleotide gene editing approaches utilising cardiomyocytes derived from DMD patients’ iPS cells, demonstrating the restoration of the dystrophin protein.

Duchenne Muscular Dystrophy Market Segment
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Duchenne Muscular Dystrophy Market Major Players and Strategies
Major players in the duchenne muscular dystrophy market are Bristol Myers Squibb Company, FibroGen Inc., Italfarmaco SpA, NS Pharma Inc., Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics Inc., BioMarin Pharmaceutical Inc., Eli Lilly and Company, GSK plc., Nippon Shinyaku Co Ltd., Acceleron Pharma, Inc., Akashi Therapeutics Inc., and Capricor Therapeutics Inc.

Solid Biosciences, a US-based life sciences firm focusing on developing and advancing a portfolio of neuromuscular and cardiac programmes, purchased AavantiBio for an undisclosed sum in December 2022. The combined business will focus on developing a variety of neuromuscular and cardiac programmes, including SGT-003, Solid’s next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy. AavantiBio, Inc. is a biotechnology firm established in the United States that is focused on creating gene therapies to improve the lives of individuals suffering from rare genetic illnesses.

The Duchenne Muscular Dystrophy Global Market Report 2023 covers regional data on duchenne muscular dystrophy market size, duchenne muscular dystrophy market trends and drivers, opportunities, strategies, and duchenne muscular dystrophy market competitor analysis. The countries covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Duchenne muscular dystrophy is a hereditary condition that causes progressive muscle loss in the skeletal, cardiac, and respiratory muscles. It is caused by a mutation in the gene that produces dystrophin, a protein that is essential for muscular function.

View More Reports Related To The Duchenne Muscular Dystrophy Market –
Genetic Testing Global Market Report 2023
Nucleic Acid Based Gene Therapy Global Market Report 2023
Genetic Testing Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: